Lantern Pharma Inc. (LTRN) Stock Forecast
LTRN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $17.50 average of analyst targets
- Upside to target
- +2,519.8% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.38
- 52-week range
- $0.67 – $4.17
LTRN analyst ratings
2 analystsNumber of analysts at each rating.
LTRN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LTRN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.38 | −$0.38 | −$0.39 | +2.6% | 1 |
| Current fiscal year (2026) | −$1.51 | −$1.51 | −$1.51 | −$1.57 | +3.8% | 1 |
| Next fiscal year (2027) | −$2.02 | −$2.02 | −$2.02 | −$1.51 | −33.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LTRN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
LTRN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LTRN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$0.38 | −$0.38 | −$0.38 | — | 0 up · 0 down |
| Current fiscal year (2026) | −$1.51 | −$1.51 | −$1.51 | −$1.51 | −$1.51 | 0.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.02 | −$2.02 | −$2.02 | −$2.02 | −$2.02 | 0.0% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LTRN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LTRN beat in 10 of 12.
What analysts expect from LTRN
2 analysts cover Lantern Pharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.50, 2,519.8% above the latest close of $0.67. Analysts expect earnings of −$1.51 per share for 2026, +3.8% from a year earlier. For 2027 the average estimate is −$2.02 per share. Lantern Pharma beat the EPS estimate in 10 of the last 12 quarters.
Related: LTRN income statement, LTRN key metrics, LTRN chart. See the LTRN stock overview for the latest quote and news.
LTRN forecast FAQ
What is Lantern Pharma's price target?
The average analyst price target for Lantern Pharma is $17.50, 2,519.8% above the latest close of $0.67.
Is Lantern Pharma a buy, hold or sell?
Of 2 analysts covering Lantern Pharma, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Lantern Pharma's EPS forecast?
Analysts forecast −$1.51 per share for 2026 (range −$1.51 to −$1.51); for 2027 the estimate is −$2.02.
When does Lantern Pharma report earnings?
Lantern Pharma is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.38.
Does Lantern Pharma usually beat earnings estimates?
Lantern Pharma reported EPS at or above the analyst estimate in 10 of the last 12 quarters.